IP attacks by Brazil and India: call for US action

20 March 2006

The Washington DC, pressure-group USA For Innovation has called for the US Trade Representative to counter what it describes as "attacks by Brazil and India on intellec-tual property rights," on the grounds that the practices authorized in both countries "severely damage the eco-nomic welfare and security of the USA." The demand comes in the form of an open letter to Rob Portman, the US ambassador to the World Trade Organization.

USA For Innovation claims that the Brazilian govern-ment is pushing the concept of "biopiracy" to justify changes in the United Nations' Convention on Biological Diversity. The group recently commissioned a research paper, by USA-based economists Robert Shapiro and Kevin Hassett, which found that the value of US intellec-tual property, including patents, ranged between $5,000.0 billion to $5,500.0 billion.

"Get tough with India and Brazil," USTR told

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.